| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,110 | 0,135 | 22.10. | |
| 0,112 | 0,133 | 22.10. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.09. | SINOMAB BIO-B (03681): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
| 28.09. | SINOMAB BIO-B (03681): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
| SINOMAB BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 28.09. | SINOMAB BIO-B (03681): INTERIM REPORT 2026 | - | HKEx | ||
| 18.09. | SINOMAB BIO-B (03681): SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO 2025 ANNUAL REPORT | - | HKEx | ||
| 07.09. | SINOMAB BIO-B (03681): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 7 SEPTEMBER 2026 | 1 | HKEx | ||
| 31.08. | SINOMAB BIO-B (03681): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026 | 1 | HKEx | ||
| 21.08. | SINOMAB BIO-B (03681): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
| 21.08. | SINOMAB BIO-B (03681): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM | 1 | HKEx | ||
| 21.08. | SINOMAB BIO-B (03681): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD AT ROOM 3, 14/F, FAIRMONT HOUSE, 8 COTTON TREE DRIVE, CENTRAL, HONG ... | 1 | HKEx | ||
| 21.08. | SINOMAB BIO-B (03681): NOTICE OF EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 21.08. | SINOMAB BIO-B (03681): (1) MAJOR TRANSACTION - DISPOSAL OF SUZHOU PROPERTY AND FACILITY; AND (2) NOTICE OF EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 19.08. | SINOMAB BIO-B (03681): DATE OF BOARD MEETING | 1 | HKEx | ||
| 18.08. | SINOMAB BIO-B (03681): BOOK CLOSURE PERIOD FOR THE EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 18.08. | SINOMAB BIO-B (03681): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 18.08. | SINOMAB BIO-B (03681): RESIGNATION OF EXECUTIVE DIRECTOR | 2 | HKEx | ||
| 10.08. | SINOMAB BIO-B (03681): FURTHER DELAY IN DESPATCH OF CIRCULAR FOR MAJOR TRANSACTION | 1 | HKEx | ||
| 27.07. | SINOMAB BIO-B (03681): DELAY IN DESPATCH OF CIRCULAR FOR MAJOR TRANSACTION | 1 | HKEx | ||
| 24.07. | SINOMAB BIO-B (03681): GRANT OF SHARE OPTIONS | 4 | HKEx | ||
| 06.07. | SINOMAB BIO-B (03681): MAJOR TRANSACTION DISPOSAL OF SUZHOU PROPERTY AND FACILITY | 3 | HKEx | ||
| 03.07. | SINOMAB BIO-B (03681): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 44,935 | +4,94 % | EQT lässt für Qiagen 9,6 Milliarden Euro springen | Der schwedische Private-Equity-Investor EQT übernimmt den europäische Molekulardiagnostik-Spezialisten Qiagen. Mit 9,6 Mrd. Euro ist die Transaktion eine der größten Übernahmen im europäischen Gesundheitssektor... ► Artikel lesen | |
| TANGO THERAPEUTICS | 27,950 | +0,07 % | Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In? | ||
| VERA THERAPEUTICS | 29,050 | 0,00 % | Vera Therapeutics plans FDA filing for IgAN drug in Q4 2026 | ||
| NURIX THERAPEUTICS | 25,510 | 0,00 % | H.C. Wainwright raises Nurix stock price target on strong revenue | ||
| KINIKSA PHARMACEUTICALS | 80,79 | 0,00 % | AstraZeneca, Cardiol Therapeutics, Kiniksa - Neue Hoffnung für Herzpatienten | Herz-Kreislauf-Erkrankungen gehören weltweit zu den größten medizinischen Herausforderungen. Während etablierte Pharmakonzerne Milliarden in neue Wirkstoffe und Künstliche Intelligenz investieren, entwickeln... ► Artikel lesen | |
| MODERNA | 181,52 | +0,45 % | Community Rückblick: BioNTech BNT113 Studie verfehlt Endpunkt: "Die Bude treibt einen zum Wahnsinn!" | © Foto: Julia Cebella - dpaBioNTech verfehlt mit BNT113 ein wichtiges Studienziel. Im wO-Forum streiten Anleger über die Zukunft der mRNA-Krebsforschung, die Bewertung der Aktie und das Potenzial der... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 36,040 | +0,03 % | Harmony Biosciences drops amid court hearing on Wakix patent | ||
| ADMA BIOLOGICS | 10,950 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 32,200 | 0,00 % | Arcutis BioTherapeutics advances 11% to new 52-week high | ||
| SUMMIT THERAPEUTICS | 15,555 | +0,03 % | Akeso, Inc.: Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer | Becomes the 7th International Registrational Clinical Trial for Ivonescimab
Clinical Trial Site Activations in the United States Expected to Begin Q4 2026
HONG... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 12,340 | 0,00 % | What's Going On with MoonLake Immunotherapeutics Stock on Thursday? | ||
| RAPPORT THERAPEUTICS | 26,530 | 0,00 % | Jones Trading raises Rapport Therapeutics price target on pipeline potential | ||
| IMMUNOME | 18,260 | 0,00 % | William Blair initiates Immunome stock coverage with outperform rating | ||
| ARCUS BIOSCIENCES | 19,320 | -0,16 % | Arcus Biosciences prices $250M public offering at $17.50 per share | ||
| RECURSION PHARMACEUTICALS | 3,580 | 0,00 % | Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast |